View Clinical Trial (Medical Research Study)

Effect of Endoplasmic Reticulum Stress on Metabolic Function - NCT00771901-63110(Clinical Trial 434988)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  St. Louis
State:  
MO
Zip Code: 63110
Conditions: Insulin Resistance - Diabetes - Obesity
Purpose: Normally, the hormone insulin works to help keep blood sugar normal. However, as a person gains weight, insulin does not work as well and blood sugar tends to be a little higher than normal. This is called "insulin resistance". Two investigational drugs (not approved by the Food and Drug Administration) for the treatment of high lipid levels or insulin resistance are being examined in this study: one drug is called tauroursodeoxycholic acid (TUDCA), the other is called sodium phenylbutyrate (PBA). This study is designed to test if TUDCA and/or PBA is effective in people who are obese with insulin resistance and high lipids. We hypothesize that pharmacologically-induced decreases in ER stress will improve insulin action and hepatic lipid metabolism in obese subjects.
Study summary: A 4-week randomized, controlled trial will be conducted to evaluate the following specific aims in obese subjects: Determine the effect of treatment with TUDCA or PBA on: 1. Body fat distribution: a) intrahepatic triglyceride (IHTG) content b) intramyocellular triglyceride (IMTG) content, and c) intra-abdominal fat content, assessed by using magnetic resonance spectroscopy and magnetic resonance imaging. 2. In vivo insulin sensitivity in adipose tissue (suppression of lipolysis), liver (suppression of glucose production), and skeletal muscle (stimulation of glucose uptake), assessed by using the hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotope tracer infusion. 3. Hepatic VLDL-triglyceride (TG) and VLDL-apolipoprotein-B100 (apoB-100) secretion rates, assessed by stable isotopically labeled tracer infusion methods. 4. Skeletal muscle intracellular insulin signaling, fatty acid oxidation, and markers of inflammation, assessed by evaluating skeletal muscle biopsies ex vivo. 5. Adipose tissue insulin signaling, ER stress, and inflammation, assessed by evaluating adipose tissue biopsies ex vivo.
Criteria: Inclusion Criteria: - BMI range 30 to 45 - sedentary (defined as regular exercise < 1 h per week or < 2 x/week for the last 6 months) Exclusion Criteria: - active or previous infection with hepatitis B or C - liver diseases - history of alcohol abuse - current alcohol consumption > 20 g/day - severe hypertriglyceridemia ( > 400 mg/dL) - active peptic ulcer disease - taking cholestyramine or oral contraceptives - women who are pregnant or lactating
Study is available at: Washington University School of Medicine
St. Louis, MO 63110
United States

Primary Contact:
Emily Jenkerson
Phone: 866-362-5656

Secondary Contact:
Emily Jenkerson
Phone: 1-866-362-5656
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 22, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.